Rhoen-Klinikum AG
- Address
- Von-Guttenberg-Strasse 11, Herschfeld, 97616 Bad Neustadt A.D.Saale, Germany
Cardiovascular Diseases and Stroke Research
At Rhoen-Klinikum AG, clinical trials focus on cardiovascular diseases with a strong emphasis on acute ischemic stroke and related cerebrovascular conditions. The studies are designed to improve prevention, treatment, and recovery after stroke, while also addressing urgent questions in stroke unit and intensive care practice.
- Testing new therapies to reduce the risk of recurrent ischemic stroke after a recent event
- Evaluating treatment options for acute cerebral ischemic stroke and functional recovery
- Studying safer and more effective care for stroke patients with complex cardiovascular risk
Research at this hospital also explores how to improve outcomes for patients with high-risk transient ischemic attack, helping refine prevention strategies in everyday clinical care.
Stroke Prevention and Antithrombotic Therapy
Several trials at the site investigate ways to prevent another stroke in people who have already experienced acute ischemic stroke or high-risk transient ischemic attack. These studies examine whether newer antithrombotic approaches can reduce future clot-related events while keeping bleeding risks low.
- Assessing new treatment strategies for preventing recurrent ischemic stroke
- Comparing therapies intended to improve protection after non-cardioembolic stroke or TIA
- Balancing effectiveness and safety, especially regarding major bleeding
This line of research is especially relevant for patients needing better long-term protection after a recent cerebrovascular event.
Acute Stroke Care in Patients on Direct Oral Anticoagulants
The site also contributes to research on emergency treatment for acute ischemic stroke in patients who have recently taken direct oral anticoagulants. These trials aim to clarify whether standard clot-busting treatment can be used more effectively and safely in this challenging group.
- Improving emergency treatment decisions for stroke patients taking DOACs
- Testing whether intravenous thrombolysis can lead to better functional recovery
- Supporting faster, evidence-based care in acute neurology
Work in this area is particularly important for Rhoen-Klinikum AG, where rapid stroke management is central to patient care.
Heart Failure, Obesity, and Atrial Fibrillation
Beyond stroke, the research portfolio includes trials in heart failure with preserved or mildly reduced ejection fraction and obesity, as well as studies in atrial fibrillation after stroke. These projects aim to improve cardiovascular outcomes, reduce hospitalizations, and lower the risk of future complications.
- Evaluating new treatments for heart failure in patients with obesity
- Studying early rhythm control for atrial fibrillation after acute ischemic stroke
- Reducing cardiovascular events and supporting better long-term recovery
Together, these studies show a broad interest in how cardiovascular disease and stroke interact, with the goal of improving both survival and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Pharmazz EU Limited1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rhoen-Klinikum AG
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-08-04 | 2023-08-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.